Proteomics of adjacent-to-tumor samples uncovers clinically relevant biological events in hepatocellular carcinoma.
hepatocellular carcinoma
heterogeneity
normal tissue adjacent to tumor
proteomics
Journal
National science review
ISSN: 2053-714X
Titre abrégé: Natl Sci Rev
Pays: China
ID NLM: 101633095
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
09
12
2022
revised:
10
05
2023
accepted:
01
06
2023
medline:
14
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
Normal adjacent tissues (NATs) of hepatocellular carcinoma (HCC) differ from healthy liver tissues and their heterogeneity may contain biological information associated with disease occurrence and clinical outcome that has yet to be fully evaluated at the proteomic level. This study provides a detailed description of the heterogeneity of NATs and the differences between NATs and healthy livers and revealed that molecular features of tumor subgroups in HCC were partially reflected in their respective NATs. Proteomic data classified HCC NATs into two subtypes (Subtypes 1 and 2), and Subtype 2 was associated with poor prognosis and high-risk recurrence. The pathway and immune features of these two subtypes were characterized. Proteomic differences between the two NAT subtypes and healthy liver tissues were further investigated using data-independent acquisition mass spectrometry, revealing the early molecular alterations associated with the progression from healthy livers to NATs. This study provides a high-quality resource for HCC researchers and clinicians and may significantly expand the knowledge of tumor NATs to eventually benefit clinical practice.
Identifiants
pubmed: 37575948
doi: 10.1093/nsr/nwad167
pii: nwad167
pmc: PMC10416816
doi:
Types de publication
Journal Article
Langues
eng
Pagination
nwad167Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of China Science Publishing & Media Ltd.
Références
Nat Rev Genet. 2020 Oct;21(10):630-644
pubmed: 32709985
Acta Biochim Biophys Sin (Shanghai). 2018 Apr 1;50(4):370-380
pubmed: 29471502
J Hepatocell Carcinoma. 2021 Dec 23;8:1623-1641
pubmed: 34993160
Clin Kidney J. 2021 May 03;14(11):2332-2337
pubmed: 34754428
Oncogene. 2022 Apr;41(17):2480-2491
pubmed: 35314790
Cancer Cell. 2022 Jan 10;40(1):70-87.e15
pubmed: 34971568
Cancer. 1953 Sep;6(5):963-8
pubmed: 13094644
Front Oncol. 2022 Jul 04;12:880100
pubmed: 35860559
N Engl J Med. 2008 Nov 6;359(19):2045-7
pubmed: 18923166
Nat Methods. 2020 Jan;17(1):41-44
pubmed: 31768060
Am J Clin Pathol. 2009 Apr;131(4):498-510
pubmed: 19289585
Cell. 2019 May 2;177(4):1035-1049.e19
pubmed: 31031003
Gastroenterology. 2014 Jan;146(1):222-32.e35
pubmed: 24055508
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
World J Surg Oncol. 2020 Jul 20;18(1):176
pubmed: 32690026
Front Oncol. 2021 Aug 19;11:700700
pubmed: 34490100
Cell Rep Methods. 2022 Sep 08;2(9):100288
pubmed: 36160043
Cell. 2020 Dec 23;183(7):1962-1985.e31
pubmed: 33242424
Cancer Res. 2015 Sep 1;75(17):3479-91
pubmed: 26269531
Front Oncol. 2014 Jun 16;4:138
pubmed: 24982845
Cancer Res. 2016 Apr 15;76(8):2394-405
pubmed: 26893476
PLoS Genet. 2011 Jun;7(6):e1002147
pubmed: 21731504
Cancer Cell. 2021 Apr 12;39(4):509-528.e20
pubmed: 33577785
Nucleic Acids Res. 2019 Jan 8;47(D1):D1211-D1217
pubmed: 30252093
Cell. 2021 Aug 5;184(16):4348-4371.e40
pubmed: 34358469
Nature. 2019 Mar;567(7747):257-261
pubmed: 30814741
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cell. 2019 Oct 31;179(4):829-845.e20
pubmed: 31675496
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
Oncogene. 2022 May;41(21):3011-3023
pubmed: 35459781
Front Immunol. 2022 Sep 06;13:944898
pubmed: 36148220
Hepatogastroenterology. 2009 Jul-Aug;56(93):1105-10
pubmed: 19760951
Nature. 2019 Oct;574(7779):538-542
pubmed: 31645727
Nat Rev Drug Discov. 2017 Jan;16(1):19-34
pubmed: 27910877
J Hematol Oncol. 2022 Jun 3;15(1):76
pubmed: 35659036
Aging (Albany NY). 2021 Apr 16;13(8):11491-11506
pubmed: 33864445
Adv Sci (Weinh). 2020 Dec 31;8(4):2001961
pubmed: 33643786
Cancer Cell. 2014 Oct 13;26(4):549-64
pubmed: 25314080
Front Oncol. 2021 Jun 04;11:678714
pubmed: 34178664
Cancer Epidemiol Biomarkers Prev. 2015 Feb;24(2):406-14
pubmed: 25465802
Proteomics. 2023 Feb;23(3-4):e2100407
pubmed: 35689503
J Hematol Oncol. 2021 Dec 11;14(1):205
pubmed: 34895304
Cancers (Basel). 2020 Feb 20;12(2):
pubmed: 32093152
Cancer Cell. 2021 Mar 8;39(3):361-379.e16
pubmed: 33417831
Genome Med. 2018 Dec 3;10(1):94
pubmed: 30501643
Cell. 2019 Oct 3;179(2):561-577.e22
pubmed: 31585088
Nat Biotechnol. 2020 Jan;38(1):90-96
pubmed: 31685958
Adv Sci (Weinh). 2023 Jun;10(17):e2205818
pubmed: 37078828
Cell. 2019 Oct 31;179(4):964-983.e31
pubmed: 31675502
Cell. 2020 Feb 20;180(4):729-748.e26
pubmed: 32059776
N Engl J Med. 2008 Nov 6;359(19):1995-2004
pubmed: 18923165
Nat Commun. 2017 Oct 20;8(1):1077
pubmed: 29057876
Cancer Cell. 2020 Nov 9;38(5):734-747.e9
pubmed: 32888432
Cell. 2020 Jul 9;182(1):245-261.e17
pubmed: 32649877
Cell. 2020 Jul 9;182(1):226-244.e17
pubmed: 32649875
Annu Rev Pathol. 2017 Jan 24;12:153-186
pubmed: 27959632
Asian Pac J Cancer Prev. 2015;16(17):7825-9
pubmed: 26625805
Cell. 2021 Sep 16;184(19):5031-5052.e26
pubmed: 34534465
J Neurosci. 2014 Aug 13;34(33):10924-36
pubmed: 25122893
Nat Med. 2021 Jun;27(6):1043-1054
pubmed: 34017133
Nat Commun. 2013;4:2612
pubmed: 24113773
Front Mol Biosci. 2022 Jun 30;9:917839
pubmed: 35847972
Cell Res. 2020 Jun;30(6):507-519
pubmed: 32467593
Genome Biol. 2017 Nov 15;18(1):220
pubmed: 29141660
Cell. 2020 Jul 9;182(1):200-225.e35
pubmed: 32649874
World J Gastroenterol. 2007 Aug 28;13(32):4345-9
pubmed: 17708609
Cell. 2020 Nov 25;183(5):1436-1456.e31
pubmed: 33212010